Neurocrine Biosciences
NBIX
#1366
Rank
A$23.34 B
Marketcap
A$234.12
Share price
0.84%
Change (1 day)
19.45%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Revenue for Neurocrine Biosciences (NBIX)

Revenue in 2025 (TTM): A$4.17 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current revenue (TTM ) is A$4.03 Billion. In 2024 the company made a revenue of A$3.78 Billion an increase over the revenue in the year 2023 that were of A$2.76 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Neurocrine Biosciences from 1996 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) A$4.17 B10.23%
2024 A$3.78 B36.71%
2023 A$2.76 B26.61%
2022 A$2.18 B39.92%
2021 A$1.56 B14.95%
2020 A$1.36 B20.85%
2019 A$1.12 B75.71%
2018 A$0.64 B209.4%
2017 A$0.20 B894.87%
2016 A$20.8 M-23.32%
2015 A$27.13 M
2014 N/A-100%
2013 A$3.27 M-93.6%
2012 A$51.13 M-32.27%
2011 A$75.49 M128.92%
2010 A$32.98 M903.28%
2009 A$3.28 M-41.65%
2008 A$5.63 M302.44%
2007 A$1.4 M-97.19%
2006 A$49.77 M-70.61%
2005 A$0.16 B53.83%
2004 A$0.11 B-41.17%
2003 A$0.18 B484.19%
2002 A$32.02 M-60.37%
2001 A$80.81 M209.72%
2000 A$26.09 M1.99%
1999 A$25.58 M-2.1%
1998 A$26.13 M-34.77%
1997 A$40.06 M65.75%
1996 A$24.16 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Repligen
RGEN
A$1.06 B-73.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$3.53 B-12.41%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$89.45 B 2,114.93%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$89.79 B 2,123.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$94.52 B 2,240.40%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$1.24 B-69.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A$0.12 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA